Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of IDP-108 in Onychomycosis
NCT01008033Phase 3Completed
- Sponsor
- Dow Pharmaceutical Sciences
- Start
- Nov 2009
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of efinaconazole in onychomycosis, sponsored by Dow Pharmaceutical Sciences. Started Nov 2009; status: completed.
02
Drugs
efinaconazole
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT01008033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01008033.